Evaluation of efficacy in improvement of reflux esophagitis by esomeprazole to the patient treated with conventional PPI. - Evaluation of efficacy in improvement of reflux esophagitis by esomeprazole to the patient treated with conventional PPI.

Kanazawa Medical University0 个研究点目标入组 50 人开始时间: 2012年6月15日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•The exclusion criteria. 1)The patient who has a history of allergy to the study drug. 2)Patient who is using atazanavir sulfate. 3)The patient with gastrointestinal diseases such as esophageal stenosis, an irritable bowel syndrome, an inflammatory bowel disease, primary esophagus motor deficit, systemic sclerosis, Zollinger-Ellison syndrome, the malabsorption syndrome and so on. 4)The patient with a gastric ulcer, and/or a duodenal ulcer endoscopically. 5)The patient with severe liver, kidney and heart disease. 6)The patient with a history of the digestive surgical operation or vagotomy. 7)Pregnant or lactation woman. 8)The patient who needs the treatment with the following drugs during the study. Exercise function improvement medicine, gastric mucosa defense factor reinforcement medicine, cholinolytic, antacid, antidepressant, an antianxiety drug, a NSAIDs, low-dose aspirin, bisphosphonate. But the patient uses it before the consent acquisition, and without during changing dosage, a dose during a study time when patient can use it, suppose that combined use is possible. 9)The patient who has to use drug having study drug and interaction. 10)Diazepam, phenytoin, cilostazol, warfarin, a tacrolimus hydrate, digoxin, metildigoxin, itraconazole, a tyrosine kinase inhibior (gefitinib, nilotinib), voriconazole, nelfinavir mesilate, saquinavir mesilate, St. John's wort component food. 11)The patient who was considered ineligible by the investigators.

发起方